Preparation and controlled release of mesoporous MCM-41/propranolol hydrochloride composite drug.
This article used MCM-41 as a carrier for the assembly of propranolol hydrochloride by the impregnation method. By means of chemical analysis, powder X-ray diffraction (XRD), scanning electron microscopy (SEM), transmission electron microscopy (TEM), Fourier transform infrared (FT-IR) spectroscopy and low-temperature N(2) adsorption-desorption at 77 K, the characterization was made for the prepared materials. The propranolol hydrochloride guest assembly capacity was 316.20 ± 0.31 mg/g (drug/MCM-41). Powder XRD test results indicated that during the process of incorporation, the frameworks of the MCM-41 were not destroyed and the crystalline degrees of the host-guest nanocomposite materials prepared still remained highly ordered. Characterization by SEM and TEM showed that the composite material presented spherical particle and the average particle size of composite material was 186 nm. FT-IR spectra showed that the MCM-41 framework existed well in the (MCM-41)-propranolol hydrochloride composite. Low-temperature nitrogen adsorption-desorption results at 77 K showed that the guest partially occupied the channels of the molecular sieves. Results of the release of the prepared composite drug in simulated body fluid indicated that the drug can release up to 32 h and its maximum released amount was 99.20 ± 0.11%. In the simulated gastric juice release pattern of drug, the maximum time for the drug release was discovered to be 6 h and the maximum cumulative released amount of propranolol hydrochloride was 45.13 ± 0.23%. The drug sustained-release time was 10 h in simulated intestinal fluid and the maximum cumulative released amount was 62.05 ± 0.13%. The prepared MCM-41 is a well-controlled drug delivery carrier.
Research Center for Nanotechnology, Changchun University of Science and Technology, Changchun, Jilin Province, P.R. China. zhaiqingzhou@163.com
Qing-Zhou
QZ
Zhai
D000319:Adrenergic beta-Antagonists / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D000327:Adsorption; D001826:Body Fluids / Q000378:metabolism; D003692:Delayed-Action Preparations / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D006801:Humans; D008954:Models, Biological; D010316:Particle Size; D016062:Porosity; D011433:Propranolol / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D012822:Silicon Dioxide / Q000737:chemistry / Q000493:pharmacokinetics
D000319:Adrenergic beta-Antagonists; D003692:Delayed-Action Preparations; C509968:MCM-41; D012822:Silicon Dioxide; D011433:Propranolol